Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Content and functional activity of von Willebrand factor in apheresis plasma

Identifieur interne : 000222 ( France/Analysis ); précédent : 000221; suivant : 000223

Content and functional activity of von Willebrand factor in apheresis plasma

Auteurs : T. Burnouf [France, Niger] ; C. Caron [France] ; T. Burkhardt [Allemagne] ; J. Goudemand [France]

Source :

RBID : ISTEX:D32E13F98B080996EE2C1EC4A23A9B3BA6290E7D

Descripteurs français

English descriptors

Abstract

Background and Objectives  Von Willebrand Factor (VWF) is a complex high‐molecular‐weight (HMW) plasma glycoprotein playing a critical role in primary and secondary haemostasis. Owing to its multimeric structure and sensitivity to proteolysis, VWF can be used as a marker of the impact of collection procedures on the characteristics of plasma for transfusion and for fractionation. We studied VWF content, functional activity and HMW multimers in plasmas collected by five different automated apheresis collection procedures. Materials and Methods  Five series of 30 plasma units were obtained from volunteer donors at two collection sites using Haemonetics PCS2 machines with Revision (Rev) F, Rev G, high‐separation core (HSC), or filter core (FC) procedures, or Baxter‐Fenwall Autopheresis‐C (Auto‐C). VWF antigen (VWF:Ag), ristocetin cofactor (VWF:RCo) activity and HMW multimers were first determined in 10 randomly selected plasma donations collected with Rev G, HSC, FC and Auto‐C procedures. Then, the same analyses and the collagen binding (VWF:CB) activity were determined in the pools of 30 donations from each of the five procedures and compared with two normal plasma pools (NPP1 and NPP2). A reference plasma (RP) was used to calibrate each assay. Results  There were a greater number of group O individuals in the Rev F, Rev G and FC donors than in the HSC and Auto‐C donors. The mean VWF:Ag level was > 100 IU/dl, VWF:RCo activity was > 90 U/dl, the VWF:RCo/Ag ratio was close to 1, and the percentage of 11–15 mers was above 100% of RP in the 10 individual plasma units from Rev G, HSC, FC, and Auto‐C and in their respective pools. The mean percentage of multimers > 15 mers, relative to RP, was significantly less in Rev G plasmas (48 ± 17%; range 32–91%), compared with Auto‐C, HSC and FC plasmas (P = 0·0211; 0·0257; and 0·0376, respectively). The VWF:CB activity of the 30‐donation pools was 61 and 60 U/dl in Auto C and HSC, 50 U/dl in Rev F and FC, and 43 U/dl in the Rev G pool. The VWF:CB/Ag ratio was 0·54 (Auto‐C), 0·49 (HSC), 0·46 (Rev F), 0·45 (FC) and 0·37 (Rev G), compared with 0·81and 0·92 in NPPs. The percentage of VWF multimers of 11–15 mers in apheresis plasma and NPP was normal. VWF multimers > 15 mers ranged from 38 to 64% of that of RP plasma, and was 111 and 112% in NPPs. Conclusions  The VWF:Ag, VWF:RCo activity and 11–15 mer VWF multimers were well preserved in all plasma units from each of the five apheresis procedures. The VWF:CB activity and the percentage of multimers > 15 mers in apheresis plasma was less than in normal plasma pools and differed slightly among procedures.

Url:
DOI: 10.1111/j.1423-0410.2004.00535.x


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:D32E13F98B080996EE2C1EC4A23A9B3BA6290E7D

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Content and functional activity of von Willebrand factor in apheresis plasma</title>
<author>
<name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name>
</author>
<author>
<name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name>
</author>
<author>
<name sortKey="Burkhardt, T" sort="Burkhardt, T" uniqKey="Burkhardt T" first="T." last="Burkhardt">T. Burkhardt</name>
</author>
<author>
<name sortKey="Goudemand, J" sort="Goudemand, J" uniqKey="Goudemand J" first="J." last="Goudemand">J. Goudemand</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D32E13F98B080996EE2C1EC4A23A9B3BA6290E7D</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1423-0410.2004.00535.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-XR0H5S0N-M/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000047</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000047</idno>
<idno type="wicri:Area/Istex/Curation">000047</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C31</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C31</idno>
<idno type="wicri:doubleKey">0042-9007:2004:Burnouf T:content:and:functional</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15260819</idno>
<idno type="wicri:Area/PubMed/Corpus">002380</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002380</idno>
<idno type="wicri:Area/PubMed/Curation">002380</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002380</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002277</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002277</idno>
<idno type="wicri:Area/Ncbi/Merge">000291</idno>
<idno type="wicri:Area/Ncbi/Curation">000291</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000291</idno>
<idno type="wicri:doubleKey">0042-9007:2004:Burnouf T:content:and:functional</idno>
<idno type="wicri:Area/Main/Merge">003205</idno>
<idno type="wicri:Area/Main/Curation">003173</idno>
<idno type="wicri:Area/Main/Exploration">003173</idno>
<idno type="wicri:Area/France/Extraction">000222</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Content and functional activity of von Willebrand factor in apheresis plasma</title>
<author>
<name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>Human Plasma Product Services, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Niger</country>
</affiliation>
</author>
<author>
<name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Burkhardt, T" sort="Burkhardt, T" uniqKey="Burkhardt T" first="T." last="Burkhardt">T. Burkhardt</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Red Cross Blood Transfusion Center Saxony, Plauen</wicri:regionArea>
<wicri:noRegion>Plauen</wicri:noRegion>
<wicri:noRegion>Plauen</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Goudemand, J" sort="Goudemand, J" uniqKey="Goudemand J" first="J." last="Goudemand">J. Goudemand</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Vox Sanguinis</title>
<title level="j" type="alt">VOX SANGUINIS</title>
<idno type="ISSN">0042-9007</idno>
<idno type="eISSN">1423-0410</idno>
<imprint>
<biblScope unit="vol">87</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="27">27</biblScope>
<biblScope unit="page" to="33">33</biblScope>
<biblScope unit="page-count">7</biblScope>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-07">2004-07</date>
</imprint>
<idno type="ISSN">0042-9007</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0042-9007</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>ABO Blood-Group System (analysis)</term>
<term>Adult</term>
<term>Antigens (blood)</term>
<term>Antigens (chemistry)</term>
<term>Antigens (pharmacology)</term>
<term>Biopolymers</term>
<term>Blood Component Removal (instrumentation)</term>
<term>Blood Component Removal (methods)</term>
<term>Calibration</term>
<term>Collagen (metabolism)</term>
<term>Endopeptidases (blood)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Weight</term>
<term>Plasma (metabolism)</term>
<term>von Willebrand Factor (analysis)</term>
<term>von Willebrand Factor (chemistry)</term>
<term>von Willebrand Factor (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antigènes ()</term>
<term>Antigènes (pharmacologie)</term>
<term>Antigènes (sang)</term>
<term>Aphérèse ()</term>
<term>Aphérèse (instrumentation)</term>
<term>Biopolymères</term>
<term>Calibrage</term>
<term>Collagène (métabolisme)</term>
<term>Endopeptidases (sang)</term>
<term>Facteur de von Willebrand ()</term>
<term>Facteur de von Willebrand (analyse)</term>
<term>Facteur de von Willebrand (pharmacologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Masse moléculaire</term>
<term>Mâle</term>
<term>Plasma sanguin (métabolisme)</term>
<term>Système ABO de groupes sanguins (analyse)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>ABO Blood-Group System</term>
<term>von Willebrand Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antigens</term>
<term>Endopeptidases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Antigens</term>
<term>von Willebrand Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Collagen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antigens</term>
<term>von Willebrand Factor</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr">
<term>Facteur de von Willebrand</term>
<term>Système ABO de groupes sanguins</term>
</keywords>
<keywords scheme="MESH" qualifier="instrumentation" xml:lang="en">
<term>Blood Component Removal</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Plasma</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Blood Component Removal</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Aphérèse</term>
<term>Collagène</term>
<term>Plasma sanguin</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antigènes</term>
<term>Facteur de von Willebrand</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Antigènes</term>
<term>Endopeptidases</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Adult</term>
<term>Apheresis</term>
<term>Apheresis plasma</term>
<term>Apheresis plasmas</term>
<term>Apheresis procedures</term>
<term>Assay</term>
<term>Biopolymers</term>
<term>Blackwell publishing</term>
<term>Blood group</term>
<term>Burnouf</term>
<term>Calibration</term>
<term>Collagen binding activity</term>
<term>Cryoprecipitate</term>
<term>Donation</term>
<term>Factor viii</term>
<term>Female</term>
<term>Functional activity</term>
<term>Greater number</term>
<term>Humans</term>
<term>Largest multimers</term>
<term>Lter core</term>
<term>Male</term>
<term>Mers</term>
<term>Middle Aged</term>
<term>Molecular Weight</term>
<term>Multimeric structure</term>
<term>Multimers</term>
<term>Normal plasma</term>
<term>Normal plasma pools</term>
<term>Npps</term>
<term>Plasma</term>
<term>Plasma donations</term>
<term>Plasma units</term>
<term>Platelet</term>
<term>Reference plasma</term>
<term>Respective pools</term>
<term>Sanguinis</term>
<term>Secondary haemostasis</term>
<term>Source plasma</term>
<term>Thromb</term>
<term>Thromb haemost</term>
<term>Transfusion</term>
<term>Viii</term>
<term>Willebrand</term>
<term>Willebrand disease</term>
<term>Willebrand factor</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antigènes</term>
<term>Aphérèse</term>
<term>Biopolymères</term>
<term>Calibrage</term>
<term>Facteur de von Willebrand</term>
<term>Femelle</term>
<term>Humains</term>
<term>Masse moléculaire</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background and Objectives  Von Willebrand Factor (VWF) is a complex high‐molecular‐weight (HMW) plasma glycoprotein playing a critical role in primary and secondary haemostasis. Owing to its multimeric structure and sensitivity to proteolysis, VWF can be used as a marker of the impact of collection procedures on the characteristics of plasma for transfusion and for fractionation. We studied VWF content, functional activity and HMW multimers in plasmas collected by five different automated apheresis collection procedures. Materials and Methods  Five series of 30 plasma units were obtained from volunteer donors at two collection sites using Haemonetics PCS2 machines with Revision (Rev) F, Rev G, high‐separation core (HSC), or filter core (FC) procedures, or Baxter‐Fenwall Autopheresis‐C (Auto‐C). VWF antigen (VWF:Ag), ristocetin cofactor (VWF:RCo) activity and HMW multimers were first determined in 10 randomly selected plasma donations collected with Rev G, HSC, FC and Auto‐C procedures. Then, the same analyses and the collagen binding (VWF:CB) activity were determined in the pools of 30 donations from each of the five procedures and compared with two normal plasma pools (NPP1 and NPP2). A reference plasma (RP) was used to calibrate each assay. Results  There were a greater number of group O individuals in the Rev F, Rev G and FC donors than in the HSC and Auto‐C donors. The mean VWF:Ag level was > 100 IU/dl, VWF:RCo activity was > 90 U/dl, the VWF:RCo/Ag ratio was close to 1, and the percentage of 11–15 mers was above 100% of RP in the 10 individual plasma units from Rev G, HSC, FC, and Auto‐C and in their respective pools. The mean percentage of multimers > 15 mers, relative to RP, was significantly less in Rev G plasmas (48 ± 17%; range 32–91%), compared with Auto‐C, HSC and FC plasmas (P = 0·0211; 0·0257; and 0·0376, respectively). The VWF:CB activity of the 30‐donation pools was 61 and 60 U/dl in Auto C and HSC, 50 U/dl in Rev F and FC, and 43 U/dl in the Rev G pool. The VWF:CB/Ag ratio was 0·54 (Auto‐C), 0·49 (HSC), 0·46 (Rev F), 0·45 (FC) and 0·37 (Rev G), compared with 0·81and 0·92 in NPPs. The percentage of VWF multimers of 11–15 mers in apheresis plasma and NPP was normal. VWF multimers > 15 mers ranged from 38 to 64% of that of RP plasma, and was 111 and 112% in NPPs. Conclusions  The VWF:Ag, VWF:RCo activity and 11–15 mer VWF multimers were well preserved in all plasma units from each of the five apheresis procedures. The VWF:CB activity and the percentage of multimers > 15 mers in apheresis plasma was less than in normal plasma pools and differed slightly among procedures.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>France</li>
<li>Niger</li>
</country>
<region>
<li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
</region>
<settlement>
<li>Lille</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Hauts-de-France">
<name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name>
</region>
<name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name>
<name sortKey="Goudemand, J" sort="Goudemand, J" uniqKey="Goudemand J" first="J." last="Goudemand">J. Goudemand</name>
</country>
<country name="Niger">
<noRegion>
<name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name>
</noRegion>
</country>
<country name="Allemagne">
<noRegion>
<name sortKey="Burkhardt, T" sort="Burkhardt, T" uniqKey="Burkhardt T" first="T." last="Burkhardt">T. Burkhardt</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000222 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000222 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:D32E13F98B080996EE2C1EC4A23A9B3BA6290E7D
   |texte=   Content and functional activity of von Willebrand factor in apheresis plasma
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021